Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
暂无分享,去创建一个
Z. Jing | H. Ghofrani | M. Madani | X. Jaïs | G. Simonneau | L. Howard | E. Mayer | A. D'armini | D. Jenkins | P. Fedullo | N. Kim | D. Richard | K. Papadakis | N. Martin